NEO Beats Neuralink: A New Era for Brain-Computer Interfaces
NEO’s Approval: A Milestone in BCI Technology
In a groundbreaking moment for the brain-computer interface (BCI) sector, NEO has outpaced several competitors, including Neuralink, the venture founded by Elon Musk. As of October 2023, Neuracle, the company behind NEO, has undertaken 36 clinical trials, including one focused on a patient named Dong. Notably, 32 of these trials took place in just a few months in 2025, showcasing the pace at which this technology is advancing. A preprint paper was released last July, detailing one of the first in-person trials, marking a significant achievement in BCI research.
Despite making this leap, Neuracle did not respond to inquiries from MIT Technology Review, a point of interest for industry watchers keen to understand more about the technology and its implications.
Understanding NEO’s Design and Approval Process
One of the key factors contributing to NEO’s swift approval is its less invasive design. While Neuralink’s N1 brain chip embeds itself within the brain’s cortex, NEO relies on eight sensors that sit on the protective membrane of the brain. This design translates to fewer regulatory hurdles, as it poses a lower risk of complications such as hemorrhage and glial scarring, explains Avinash Singh, a BCI researcher at the University of Technology Sydney.
Moreover, the robust support for BCIs in China has facilitated an expedited regulatory pathway for NEO, contrasting with the lengthy approval timelines often experienced with the U.S. Food and Drug Administration. This streamlined process is pivotal for rapidly evolving technologies like BCI.
Implications for the Global BCI Industry
The approval of NEO represents a major breakthrough not just for Neuracle, but also for the entire global BCI landscape. As Wang Shouyan, a neuroscientist at Fudan University, emphasizes, despite decades of research in BCIs, most has remained experimental. NEO’s entry into the market is a clear signal that BCIs are poised for mass production and clinical applications in China.
More Read
For patients like Dong, the implications are deeply personal. He notes, “Now, it will be able to help not only me but also thousands and thousands of other patients suffering from spinal cord injuries in China who are tortured by despair each day.” Such sentiments resonate with many who have been seeking hope and effective treatment options for debilitating conditions.
Integration into Healthcare Systems
Following its approval, NEO has already started to be integrated into China’s health insurance system, a significant step toward making this technology accessible. The assignment of a unique code for NEO means that eligible patients can expect to pay a percentage of the device’s cost as part of their treatment, creating a more sustainable model for healthcare in the face of emerging technologies.
The Future of China’s BCI Industry
China’s commitment to the BCI sector is further highlighted by the recent five-year plan, which identifies BCI as one of six crucial industries for the country’s technological competitiveness. With significant policy support and financial backing, the growth trajectory for BCIs in China is set to accelerate. Companies like NeuroXess and StairMed are already making strides in the field, adding to a robust ecosystem that fosters innovation.
Meicen Sun, an information scientist at the University of Illinois Urbana-Champaign, notes that China’s governmental focus is partly influenced by the accomplishments of these startups. Their success lays the groundwork for a future where China emerges as a global leader in the BCI arena.
Conclusion
The journey of NEO symbolizes not just a triumph for Neuracle and its innovative technology but also a pivotal moment for the broader BCI industry. As it garners approval and integrates into healthcare systems, the potential to transform lives, particularly for those with spinal cord injuries, is profound. With continued support and advancements, the landscape of BCI technology is poised for exciting developments in the years to come.
Inspired by: Source
